Standard BioTools Inc (NASDAQ: LAB) kicked off on Tuesday, up 4.03% from the previous trading day, before settling in for the closing price of $1.24. Over the past 52 weeks, LAB has traded in a range of $0.92-$2.32.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 11.61%. While this was happening, its average annual earnings per share was recorded 66.03%. With a float of $365.43 million, this company’s outstanding shares have now reached $381.69 million.
Standard BioTools Inc (LAB) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of Standard BioTools Inc is 4.34%, while institutional ownership is 74.11%. The most recent insider transaction that took place on Aug 22 ’25, was worth 252,680. In this transaction Director of this company bought 200,000 shares at a rate of $1.26, taking the stock ownership to the 59,950,000 shares. Before that another transaction happened on Aug 25 ’25, when Company’s Director bought 200,000 for $1.24, making the entire transaction worth $248,180. This insider now owns 60,150,000 shares in total.
Standard BioTools Inc (LAB) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.03 earnings per share (EPS), higher than consensus estimate (set at -0.08) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 66.03% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 39.44% during the next five years compared to 11.61% growth over the previous five years of trading.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
Take a look at Standard BioTools Inc’s (LAB) current performance indicators. Last quarter, stock had a quick ratio of 4.92. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.32, a number that is poised to hit -0.04 in the next quarter and is forecasted to reach -0.15 in one year’s time.
Technical Analysis of Standard BioTools Inc (LAB)
Looking closely at Standard BioTools Inc (NASDAQ: LAB), its last 5-days average volume was 1.24 million, which is a drop from its year-to-date volume of 1.74 million. As of the previous 9 days, the stock’s Stochastic %D was 66.82%.
During the past 100 days, Standard BioTools Inc’s (LAB) raw stochastic average was set at 55.22%, which indicates a significant decrease from 77.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0722 in the past 14 days, which was lower than the 0.0847 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2761, while its 200-day Moving Average is $1.3807. However, in the short run, Standard BioTools Inc’s stock first resistance to watch stands at $1.3133. Second resistance stands at $1.3367. The third major resistance level sits at $1.3833. If the price goes on to break the first support level at $1.2433, it is likely to go to the next support level at $1.1967. Should the price break the second support level, the third support level stands at $1.1733.
Standard BioTools Inc (NASDAQ: LAB) Key Stats
The company with the Market Capitalisation of 492.77 million has total of 381,995K Shares Outstanding. Its annual sales at the moment are 174,430 K in contrast with the sum of -138,890 K annual income. Company’s last quarter sales were recorded 21,760 K and last quarter income was -33,460 K.
